Subtotal: KSh17,500.00
Tirzepatide is a next-generation peptide that activates both GIP (Glucose-Dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) receptors. This dual-action mechanism makes it one of the most innovative developments in metabolic health and weight management science.
Originally developed for the management of type 2 diabetes, Tirzepatide has gained global attention for its effects on appetite regulation, blood sugar control, and body weight reduction when used alongside healthy lifestyle interventions.
Tirzepatide works by mimicking two naturally occurring hormones involved in metabolism and appetite regulation.
✔ Supports appetite regulation
✔ Promotes feelings of fullness
✔ Slows gastric emptying
✔ Supports blood sugar management
✔ Supports insulin response
✔ Contributes to glucose regulation
✔ May enhance metabolic efficiency
The combination of GIP and GLP-1 receptor activity is what makes Tirzepatide distinct from traditional GLP-1-only therapies.
Tirzepatide acts on brain pathways involved in appetite regulation and calorie intake.
Clinical studies have demonstrated significant reductions in body weight when combined with diet and lifestyle changes.
Tirzepatide improves glycemic control by supporting insulin secretion in a glucose-dependent manner while reducing glucagon secretion.
Research continues to explore its broader role in metabolic wellness and cardiometabolic health.
Unlike semaglutide and other traditional GLP-1 medications that target a single receptor, Tirzepatide targets:
✔ GLP-1 Receptors
✔ GIP Receptors
This dual-action approach has made Tirzepatide one of the most studied metabolic therapies in recent years.
🧬 Advanced Dual-Receptor Technology
⚡ Once-Weekly Administration
🔥 Appetite Regulation Support
💉 Metabolic Health Innovation
📊 Clinically Studied Mechanism
🌍 Globally Recognized Peptide Therapy
Tirzepatide is a dual GIP and GLP-1 receptor agonist used in the management of type 2 diabetes and approved in some jurisdictions for chronic weight management in eligible adults.
Most formulations are administered as a once-weekly subcutaneous injection.
Semaglutide primarily targets GLP-1 receptors, while Tirzepatide activates both GLP-1 and GIP receptors.
Commonly reported side effects include nausea, vomiting, diarrhea, constipation, and other gastrointestinal symptoms. Patients should discuss risks and benefits with a qualified healthcare professional.
At Oak Pharmaceuticals, we are committed to providing premium-quality peptide products backed by scientific innovation, product quality, and professional customer support.
✔ Premium Quality Standards
✔ Advanced Biotechnology Solutions
✔ Nationwide Delivery Across Kenya
✔ Dedicated Customer Support
✔ Trusted Peptide Supplier
Reviews
There are no reviews yet.